Taking people in BelgiumPhase 3
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Key facts
- Where
- Edegem, Leuven, Liège, Roeselare, and Sint-Lambrechts-Woluwe, BelgiumSee the 5 sites
- Phase
- Phase 3
Where in Belgium
- Antwerp University HospitalEdegem, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumTaking people
- Algemeen Ziekenhuis DeltaRoeselare, BelgiumTaking people
- Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lakefront Biotherapeutics
- Trial code
- EU 2023-510173-34-00
- Record updated
- 11 September 2026
- Original description
To evaluate the long-term safety of GLPG CAR T cell products for up to 15 years post CAR T cell product infusionRead full original descriptionShow less
A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
To evaluate the long-term safety of GLPG CAR T cell products for up to 15 years post CAR T cell product infusion
Inclusion: Subject must sign and date the ICF as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any study-related procedures; Subjects has been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program.
Exclusion: There are no exclusion criteria for this study.